Full-Life Technologies Announces U.S. FDA IND Clearance and Australian Regulatory Clearance for [²²⁵Ac]Ac-FL-261 Phase 1 Clinical Trial

Full-Life Technologies announced that the FDA has cleared an unspecified company submission related to its clinical-stage actinium-based radiopharmaceutical platform. The provided article text is truncated and does not disclose the specific program, indication, trial details, or financial implications. The regulatory clearance is a positive development for the privately held biotech company but is unlikely to have broad public-market impact.